Oxygen Biotherapeutics, Inc. (OXBT.OB) Clinical Trial for Traumatic Brain Injury Treatment Enrolls First Patient
Oxygen Biotherapeutics, Inc. announced today enrollment of its first patient in Phase II-b clinical trials for a new drug. The trial, which is to take place in Switzerland, will utilize OXBT’s perfluorocarbon (PFC) therapeutic oxygen carrier, Oxycyte(TM), in emulsion form for the treatment of traumatic brain injury (TBI). Chairman and CEO of OXBT Chris Stern noted the “invaluable importance” of the drug for enhancing TBI sufferer’s recovery, touting Oxycyte as long awaited proof of a “safe and effective treatment for this devastating injury.” Stern restored shareholder morale lost over the extended period preceding initial patient dosing, explaining that the on-site…